All data are based on the daily closing price as of November 12, 2026
a
Alar Pharmaceuticals
6785.TWO
2.46 USD
0.02
+0.82%
Overview
Last close
2.46 usd
Market cap
164.03M usd
52 week high
9.84 usd
52 week low
2.25 usd
Target price
8.8 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
1781.3334
Price/Book Value
2.2511
Enterprise Value
93.10M usd
EV/Revenue
1022.546
EV/EBITDA
413.1064
Key financials
Revenue TTM
91047.04 usd
Gross Profit TTM
78664.64 usd
EBITDA TTM
-5.11M usd
Earnings per Share
-0.03 usd
Dividend
N/A usd
Total assets
77.04M usd
Net debt
N/A usd
About
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.